Enliven Therapeutics (ELVN) Cash from Operations (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Cash from Operations data on file, last reported at 19291000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 20.04% year-over-year to 19291000.0; the trailing twelve-month figure through Mar 2026 stood at 65465000.0 (up 11.48% YoY), and the FY2025 full-year result was 70301000.0, up 3.95% from the prior year.
• Cash from Operations slipped to 19291000.0 in Q1 2026, from 15838000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 6447000.0 in Q3 2022 to a low of 24127000.0 in Q1 2025.
• A 5-year average of 15066470.59 and a median of 15838000.0 in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 40.86% in 2022 and tumbled 146.53% in 2023, its largest moves.
• Tracing ELVN's Cash from Operations over 5 years: stood at 8145000.0 in 2022, then tumbled by 53.25% to 12482000.0 in 2023, then plunged by 37.82% to 17203000.0 in 2024, then grew by 7.93% to 15838000.0 in 2025, then retreated by 21.8% to 19291000.0 in 2026.
• Business Quant data shows ELVN's Cash from Operations at 19291000.0 in Q1 2026, 15838000.0 in Q4 2025, and 13279000.0 in Q3 2025.